Husain K Khambati1, Toni K Choueiri2, Christian K Kollmannsberger3, Scott North4, George A Bjarnason5, Ulka N Vaishampayan6, Lori Wood7, Jennifer J Knox8, Min-Han Tan9, Mary J MacKenzie10, Frede Donskov11, Brian I Rini12, Daniel Y C Heng13. 1. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 2. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. 3. Vancouver Cancer Center, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 4. Cross Cancer Institute, Edmonton, Alberta, Canada. 5. Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. 6. Karmanos Cancer Institute, Wayne State University, Detroit, MI. 7. Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. 8. Princess Margaret Hospital, Toronto, Ontario, Canada. 9. National Cancer Center, Singapore. 10. London Regional Cancer Program, London, Ontario, Canada. 11. Aarhus University, Aarhus, Denmark. 12. Cleveland Clinic Taussig Cancer Center, Cleveland, OH. 13. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. Electronic address: daniel.heng@albertahealthservices.ca.
Abstract
INTRODUCTION/ BACKGROUND: Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS: Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers. Patient characteristics, data on second-line therapy, and outcomes including treatment duration and overall survival, were evaluated using summary statistics and multivariate analysis. RESULTS: All patients (n = 1381) were treated with front-line targeted therapy; 144 (10%) were 75 years old or older. Six patients (4%) were favorable risk, 99 patients (69%) intermediate risk, and 39 patients (27%) poor risk according to Heng Journal of Clinical Oncology 2009 prognostic factors. The initial treatment for those ≥ 75 years of age was sunitinib (n = 98), sorafenib (n = 35), bevacizumab (n = 7), and AZD217 (n = 4). Twenty-three percent of older patients and 39% of the younger patients went on to receive second-line therapy (P < .0001). The overall response rate, median treatment duration, and overall survival for the older versus younger group were 18% versus 25% (P = .0975), 5.5 months versus 7.5 months (P = .1388), and 16.8 months versus 19.7 months (P = .3321), respectively. When adjusted for poor prognostic factors, age 75 years and older was not found to be associated with poorer overall survival (hazard ratio [HR], 1.002; 95% confidence interval [CI], 0.781-1.285) or shorter treatment duration (HR, 1.018; 95% CI, 0.827-1.252). The retrospective study design was the primary limitation. CONCLUSION: The use of advanced age as a selection criterion for targeted therapy requires further study, with data suggesting no clinically meaningful differences in overall response rate, treatment duration, and overall survival between older and younger age groups.
INTRODUCTION/ BACKGROUND: Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS: Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers. Patient characteristics, data on second-line therapy, and outcomes including treatment duration and overall survival, were evaluated using summary statistics and multivariate analysis. RESULTS: All patients (n = 1381) were treated with front-line targeted therapy; 144 (10%) were 75 years old or older. Six patients (4%) were favorable risk, 99 patients (69%) intermediate risk, and 39 patients (27%) poor risk according to Heng Journal of Clinical Oncology 2009 prognostic factors. The initial treatment for those ≥ 75 years of age was sunitinib (n = 98), sorafenib (n = 35), bevacizumab (n = 7), and AZD217 (n = 4). Twenty-three percent of older patients and 39% of the younger patients went on to receive second-line therapy (P < .0001). The overall response rate, median treatment duration, and overall survival for the older versus younger group were 18% versus 25% (P = .0975), 5.5 months versus 7.5 months (P = .1388), and 16.8 months versus 19.7 months (P = .3321), respectively. When adjusted for poor prognostic factors, age 75 years and older was not found to be associated with poorer overall survival (hazard ratio [HR], 1.002; 95% confidence interval [CI], 0.781-1.285) or shorter treatment duration (HR, 1.018; 95% CI, 0.827-1.252). The retrospective study design was the primary limitation. CONCLUSION: The use of advanced age as a selection criterion for targeted therapy requires further study, with data suggesting no clinically meaningful differences in overall response rate, treatment duration, and overall survival between older and younger age groups.
Authors: George R Prout; Margaret N Wesley; Rosemary Yancik; Lynn A G Ries; Richard J Havlik; Brenda K Edwards Journal: Cancer Date: 2005-10-15 Impact factor: 6.860
Authors: Michael D Gillett; John C Cheville; R Jeffrey Karnes; Christine M Lohse; Eugene D Kwon; Bradley C Leibovich; Horst Zincke; Michael L Blute Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Bradley C Leibovich; Ken-ryu Han; Matthew H T Bui; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie Belldegrun Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: Shahrokh F Shariat; John P Sfakianos; Michael J Droller; Pierre I Karakiewicz; Siegfried Meryn; Bernard H Bochner Journal: BJU Int Date: 2009-11-13 Impact factor: 5.588
Authors: Christian Beisland; Tom B Johannesen; Olbjorn Klepp; Ulrika Axcrona; Knut Martin Torgersen; Jan Kowalski; Oddvar Solli; Rickard Sandin; Jan Oldenburg Journal: Onco Targets Ther Date: 2017-01-16 Impact factor: 4.147